New opioid aims to quiet cough during anesthesia
NCT ID NCT07660380
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests whether oliceridine, a newer opioid, causes less coughing than the standard drug sufentanil when given at the start of general anesthesia. Coughing during this phase can be dangerous, especially for patients with high pressure in the head or eyes. The study involves adults scheduled for elective surgery and will measure cough frequency, severity, and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Oliceridine
What this could lead to
If oliceridine causes less coughing than sufentanil during anesthesia induction, it could become a safer option for patients, especially those at risk of complications from coughing.
What could go wrong
This is a small, single-center trial, so results may not apply to all patients. Oliceridine may not reduce cough as hoped, or could have other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANESTHESIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianmen First People's Hospital
Tianmen, Hubei, 431700, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••